Based on the earnings transcript, I anticipate a modestly positive short-term impact on Johnson & Johnson's stock price over the next 1-2 weeks. While there are some near-term headwinds like ESA market declines and upcoming patent expirations, management demonstrated strong execution with solid 2007 results (beating guidance), provided stable 2008 guidance, and outlined compelling long-term growth strategies across their diversified businesses. The company's financial discipline, ongoing share repurchase program, and strong pipeline progress should provide support to the stock.

[1]